Close

Abeona Therapeutics (ABEO) Announces DSMB Approval of ABO-102 Dose Escalation in Phase 1/2 Second Cohort for Sanfilippo Syndrome Type A

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/25/2024

1. META
2. CMG
3. LRCX
4. IBM
5. SPY
6. HCP
7. BSX
8. NOW
9. SNAP
10. PI


Go back to Abeona Therapeutics (ABEO) Announces DSMB Approval of ABO-102 Dose Escalation in Phase 1/2 Second Cohort for Sanfilippo Syndrome Type A
(NASDAQ: ABEO) Delayed: 3.15 -0.02 (0.63%)
Previous Close $3.17    52 Week High $9.44 
Open $3.17    52 Week Low $2.05 
Day High $3.28    P/E N/A 
Day Low $3.05    EPS $0.00 
Volume 966,871